plerixafor has been researched along with isoproterenol in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Dhume, A; Hadri, L; Hajjar, RJ; Jarrah, AA; LaRocca, T; Schecter, AD; Schwarskopf, M; Tarzami, ST; Wang, ER; Zhang, S | 1 |
1 review(s) available for plerixafor and isoproterenol
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for plerixafor and isoproterenol
Article | Year |
---|---|
SDF-1 induces TNF-mediated apoptosis in cardiac myocytes.
Topics: Animals; Apoptosis; Benzylamines; Caspase 3; Chemokine CXCL12; Cyclams; Dose-Response Relationship, Drug; Doxorubicin; Gene Expression Regulation; Heterocyclic Compounds; Isoproterenol; Mitochondria; Myocytes, Cardiac; Primary Cell Culture; Rats; Rats, Sprague-Dawley; Receptors, CXCR4; Signal Transduction; Tumor Necrosis Factor-alpha | 2018 |